Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort

Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort: reply

“…Sir , We thank Al Arashi et al [1] for their interest and comments on our recent report on tumour necrosis factor inhibitor (TNFi) survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort [2].…”

“…In conclusion, there are differences between our cohort and those reported by Al Arashi et al . [1]; however, sample sizes are small. Larger prospective studies are required to evaluate sex differences in axSpA.…”